This study was carried out on a collection of both primary and recurrent patient-derived GBM tumor biopsy cell lines in addition to the commercially available U251 and A172 lines with the aim of identifying the true potential which MRP1 inhibition may play in primary or recurrent GBM tumor treatment. The gene discussed is ABCC1; the disease is glioblastoma.